AstraZeneca, HKUST sign MoU on life sciences R&D

The two will apply AI and machine learning to the life sciences.

AstraZeneca Hong Kong and The Hong Kong University of Science and Technology (HKUST) have signed a Memorandum of Understanding (MoU) to accelerate research and development (R&D) in the city’s life sciences ecosystem.

Another central focus will be applying artificial intelligence (AI) and machine learning (ML) to the life sciences domain, by uniting AstraZeneca’s clinical expertise with HKUST’s work in computational biology.

This will enhance medical diagnostics and pathological image analysis, optimising precision treatment, generating high-quality real-world evidence, and improving healthcare delivery.

Additionally, it will develop effective treatment strategies for major metabolic disorders, including respiratory, cardiovascular, and renal disorders.

The two will also pioneer new therapeutic approaches in precision cancer treatment, extending to innovative solutions for rare diseases.

It was signed by the Head of Medical Affairs, BioPharmaceuticals & Rare Disease of AstraZeneca, Tin Hung Wong, and Vice-President for Research and Development at HKUST, Tim Cheng.